整合新技术以多学科方法诊治原发性肝脏肿瘤:下一代肿瘤委员会
本文综述原发性肝脏肿瘤(含良性肝脏肿瘤、肝细胞癌和胆管癌)多学科肿瘤委员会(MDTB)的现状与未来。文章指出精准医学要求跨学科协作,未来十年人工智能、分子生物学、病理学和先进影像将融合,需调整MDTB结构并加强研究素养。
要点
- MDTB由外科、放射、肿瘤、病理、肝病和放疗科等专业团队组成,提出个体化治疗方案。
- 系统性及局部区域治疗选择增多,分子生物学与人工智能有望未来整合进MDTB。
- 未来十年需调整MDTB结构以纳入前沿技术,并提升对人工智能和新技术的素养。
核心结论
- 未来十年预计人工智能、分子生物学、病理学和先进影像将融合,需调整MDTB结构以纳入这些前沿技术。
- 驾驭这一演变需加强基础、转化和临床研究,并通过升级MDTB作为科学协作枢纽来促进临床试验。
研究设计与样本
- 综述,阐述原发性肝脏肿瘤临床管理中的未满足需求及作者对未来MDTB角色的观点。
主要发现
- 原发性肝脏肿瘤包括良性肝脏肿瘤、肝细胞癌和胆管癌,呈现多方面挑战,需协作方法。
- MDTB涉及外科、放射、肿瘤、病理、肝病和放疗科等专业团队共同提出个体化治疗方案。
- 原发性肝癌治疗格局演变带来复杂性,尤其是系统性及局部区域治疗选择扩大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary liver tumours, including benign liver tumours, hepatocellular carcinoma and cholangiocarcinoma, present a multifaceted challenge, necessitating a collaborative approach, as evidenced by the role of the multidisciplinary tumour board (MDTB). The approach to managing primary liver tumours involves specialised teams, including surgeons, radiologists, oncologists, pathologists, hepatologists, and radiation oncologists, coming together to propose individualised treatment plans. The evolving landscape of primary liver cancer treatment introduces complexities, particularly with the expanding array of systemic and locoregional therapies, alongside the potential integration of molecular biology and artificial intelligence (AI) into MDTBs in the future. Precision medicine demands collaboration across disciplines, challenging traditional frameworks. In the next decade, we anticipate the convergence of AI, molecular biology, pathology, and advanced imaging, requiring adaptability in MDTB structure to incorporate these cutting-edge technologies. Navigating this evolution also requires a focus on enhancing basic, translational, and clinical research, as well as boosting clinical trials through an upgraded use of MDTBs as hubs for scientific collaboration and raising literacy about AI and new technologies. In this review, we will delineate the current unmet needs in the clinical management of primary liver cancers, discuss our perspective on the future role of MDTBs in primary liver cancers ("next generation" MDTBs), and unravel the potential power and limitations of novel technologies that may shape the multidisciplinary care landscape for primary liver cancers in the coming decade.
引用
- Nault JC, Calderaro J, Ronot M, et al. Integration of new technologies in the multidisciplinary approach to primary liver tumours: The next-generation tumour board. J Hepatol. 2024. PMID: 38871125. doi:10.1016/j.jhep.2024.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。